EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Patient-Specific Modifiers of Survival Benefit in Cardiac Resynchronization Therapy - A Multicentre Interaction Analysis

Bert Vandenberk, Marius Brusselmans, Gabor Voros, Pieter Martens, Sebastian Ingelaere, Pascal Betschart, Jens-Uwe Voigt, Matthias Dupont, Alexander Breitenstein, Jan Steffel, Rik Willems, Frank Ruschitzka und 3 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15367 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Bert Vandenberk und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, UZ Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Cardiac Resynchronization Therapy, Heart Failure, Registries, Stroke Volume. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Frans Van de Werf Fund for Clinical Cardiovascular Research, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Fund for Scientific Research Flanders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiac resynchronization therapy (CRT) is a key intervention for patients with heart failure. The choice between a CRT with defibrillator therapy (CRT-D) and a CRT with pacemaker (CRT-P) is influenced by individual clinical characteristics. This study explores the interaction between these clinical variables and the benefit of CRT-D versus CRT-P on all-cause mortality.

Methods

All patients who underwent CRT implantation in three European centres were included in a multicentre, retrospective registry. The impact of clinical variables on all-cause mortality was analysed using interaction tests within multivariable Cox proportional hazard models. Significant interactions were explored to assess how patient characteristics modify the effect of CRT-D compared with CRT-P.

Results

A total of 2271 patients with CRT implantation were included. CRT-D was associated with a 35% reduction in all-cause mortality compared with CRT-P [hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.53–0.80]. Significant interactions were observed for left bundle branch block (LBBB) morphology (P = 0.028), left ventricular ejection fraction (LVEF, P = 0.025) and renal function (P = 0.019). The survival benefit of CRT-D was pronounced in patients with LBBB (HR 0.57; 95% CI 0.44–0.73) but was not significant in those without LBBB (HR 0.81; 95% CI 0.59–1.10). For LVEF at implant, CRT-D provided benefit between 17.9% and 37.6%. Similarly, CRT-D improved outcomes in patients with an estimated glomerular filtration rate >31.8 mL/min but not in those with more advanced renal impairment. No interaction was observed with age at implant (P = 0.286).

Conclusions

This study provides insights into the benefits of CRT-D over CRT-P, identifying LBBB morphology, LVEF and renal function as key covariates associated with implantable cardioverter–defibrillator (ICD) therapy's benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiac Resynchronization TherapyHeart FailureRegistriesStroke VolumeVentricular Function, LeftDefibrillators, ImplantableHumansMaleFemaleRetrospective StudiesAgedSurvival RateMiddle AgedFollow-Up StudiesEuropeCause of Death

Stichwörter der Autor:innen

cardiac resynchronization therapyheart failureimplantable cardioverter–defibrillatorpacemaker

Autor:innen und Institutionen

  • Department of Cardiology, UZ Leuven, Leuven, Belgium.
  • Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
  • Department of Clinical and Epidemiological Virology, KU Leuven, Leuven, Belgium.
  • Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.
  • Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Life Sciences, Hasselt University, Hasselt, Belgium.

Förderung

  • Frans Van de Werf Fund for Clinical Cardiovascular Research
  • Fonds voor Wetenschappelijk Onderzoek-Vlaanderen
  • Fund for Scientific Research Flanders
  • Fonds voor Wetenschappelijk Onderzoek—Vlaanderen

Zitieren

APA

Vandenberk, B., Brusselmans, M., Voros, G., Martens, P., Ingelaere, S., Betschart, P., Voigt, J. U., Dupont, M., Breitenstein, A., Steffel, J., Willems, R., Ruschitzka, F., Mullens, W., Trenson, S., & Winnik, S. (2025). Patient-Specific Modifiers of Survival Benefit in Cardiac Resynchronization Therapy - A Multicentre Interaction Analysis. ESC Heart Failure. https://doi.org/10.1002/ehf2.15367

Vancouver

Vandenberk B, Brusselmans M, Voros G, Martens P, Ingelaere S, Betschart P, et al. Patient-Specific Modifiers of Survival Benefit in Cardiac Resynchronization Therapy - A Multicentre Interaction Analysis. ESC Heart Failure. 2025. doi:10.1002/ehf2.15367

BibTeX
@article{Vandenberk2025,
  author = {Vandenberk, Bert and Brusselmans, Marius and Voros, Gabor and Martens, Pieter and Ingelaere, Sebastian and Betschart, Pascal and Voigt, Jens-Uwe and Dupont, Matthias and Breitenstein, Alexander and Steffel, Jan and Willems, Rik and Ruschitzka, Frank and Mullens, Wilfried and Trenson, Sander and Winnik, Stephan},
  title = {Patient-Specific Modifiers of Survival Benefit in Cardiac Resynchronization Therapy - A Multicentre Interaction Analysis},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15367}
}
Kostenlos starten →